PubMed · 2002 · 213 citations · 43 references
MedicineOncologyPathologyGastrointestinal OncologyMetastasisMolecular OncologyAngiogenesisAngiogenesis In CancerCancer Cell SignalingColorectal CancerMalignant NeoplasmsMalignant TumorsAngiogenesis In NeoplasmsColorectal AdenomasColorectal Cancer PathologyGastrointestinal MucosaPrognostic BiomarkersPrognostic Marker AssessmentTumor Differentiation AssessmentVascular Endothelial Growth Factor
The angiogenic factor vascular endothelial growth factor-D (VEGF-D) isa ligand for VEGF receptor-3 (VEGFR-3/Flt-4) and receptor-2 (VEGFR-2/KDR)and is implicated in the development of lymphatic vessels and promotion of lymphatic metastases. We assessed the expression of VEGF-D and VEGFR-3 in relation to microvessel density (MVD) in colorectal carcinomas (CRC), adenomas, and adjacent normal tissue by immunohistochemistry on consecutive archival sections. VEGF-D was detected in malignant and benign epithelium and in some smooth muscle of the colorectum. High-grade VEGF-D expression was observed frequently (74%) in CRC compared with adenomas (0%) and adjacent normal mucosa (22%). High-grade VEGF-D expression was not correlated with MVD, Dukes' stage (A to C), or tumor differentiation, but was associated with lymphatic involvement and patient survival. By multivariate analysis, VEGF-D expression was found to be an independent prognostic factor for both disease-free and overall survival. VEGFR-3 expression was detected in a subset of vessels, typically thin-walled and devoid of RBCs, in 89% of CRC cases examined. VEGFR-3-positive vessel densities increased progressively from normal mucosa to adenomas and carcinomas and were correlated with MVD, but not with Dukes' stage (A to C), tumor differentiation, or VEGF-D expression. VEGFR-3 expression was spatially associated with macrophage-rich inflammatory infiltrates, which were significantly more frequent among VEGFR-3-positive cases. We conclude that VEGF-D expression, but not that of its receptor VEGFR-3, is an independent prognostic indicator in CRC. VEGF-D expression may be associated with disease outcome through the promotion of lymphatic involvement/metastases.
43
VEGF-D promotes the metastatic spread of tumor cells via the lymphatics
Steven A. Stacker, Carol Caesar, Megan E. Baldwin et al. · Nature Medicine · 2001 · 1.2K citations
Medicine, Cancer Biology, Oncology +14
Marc G. Achen, Michael Jeltsch, Eola Kukk et al. · Proceedings of the National Academy of Sciences · 1998 · 1.2K citations
Cardiovascular Failure in Mouse Embryos Deficient in VEGF Receptor-3
Daniel Dumont, Lotta Jussila, Jussi Taipale et al. · Science · 1998 · 878 citations
Life Sciences, Developmental Biology, Molecular Genetics +17